Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Recurrence 1Multiple Myeloma 1Gliosarcoma 1Glioma 1Ependymoma 1Disease Progression 1Brain Neoplasms 1

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioma × marizomib × Clear all
NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡